EA201200764A1 - Производные хиназолина - Google Patents

Производные хиназолина

Info

Publication number
EA201200764A1
EA201200764A1 EA201200764A EA201200764A EA201200764A1 EA 201200764 A1 EA201200764 A1 EA 201200764A1 EA 201200764 A EA201200764 A EA 201200764A EA 201200764 A EA201200764 A EA 201200764A EA 201200764 A1 EA201200764 A1 EA 201200764A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
hinazolin
hsp90
medicament
inhibition
Prior art date
Application number
EA201200764A
Other languages
English (en)
Inventor
Ханс-Михаэль Эггенвайлер
Кристиан Зирренберг
Ханс-Петер Бухшталлер
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201200764A1 publication Critical patent/EA201200764A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Новые производные хиназолинамида формулы (I)в которой R-Rи Х имеют значения, указанные в п.1, являются ингибиторами HSP90 и могут применяться для приготовления лекарственного средства для лечения заболеваний, на которые влияет ингибирование, регуляция и/или модуляция HSP90.
EA201200764A 2009-11-23 2010-10-26 Производные хиназолина EA201200764A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009054302A DE102009054302A1 (de) 2009-11-23 2009-11-23 Chinazolinderivate
PCT/EP2010/006537 WO2011060873A1 (de) 2009-11-23 2010-10-26 Chinazolinderivate

Publications (1)

Publication Number Publication Date
EA201200764A1 true EA201200764A1 (ru) 2012-12-28

Family

ID=43304809

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200764A EA201200764A1 (ru) 2009-11-23 2010-10-26 Производные хиназолина

Country Status (15)

Country Link
US (1) US8906930B2 (ru)
EP (1) EP2504314B1 (ru)
JP (1) JP5841059B2 (ru)
KR (1) KR20120101085A (ru)
CN (1) CN102648178B (ru)
AR (1) AR081117A1 (ru)
AU (1) AU2010321264B2 (ru)
BR (1) BR112012012000A2 (ru)
CA (1) CA2781380C (ru)
DE (1) DE102009054302A1 (ru)
EA (1) EA201200764A1 (ru)
ES (1) ES2548027T3 (ru)
IL (1) IL219872A (ru)
MX (1) MX2012005811A (ru)
WO (1) WO2011060873A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2578990T3 (es) 2009-03-21 2016-08-03 Sunshine Lake Pharma Co., Ltd. Derivados de amino éster, sales de los mismos y métodos de uso
US10138212B2 (en) 2015-02-06 2018-11-27 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as A2A antagonist
EP3317278B1 (en) * 2015-07-01 2021-04-14 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
AU3378599A (en) 1998-04-03 1999-10-25 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
JP2003523313A (ja) 1999-03-12 2003-08-05 アメリカ合衆国 シャペロン蛋白質の阻害方法
WO2001072779A1 (en) 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
AU2001271567A1 (en) 2000-06-29 2002-01-14 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
CA2416603A1 (en) 2000-07-20 2003-01-31 Merck & Co., Inc. Inhibiting hepatitis c virus processing and replication
AU2001292548B2 (en) 2000-07-28 2005-06-16 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
CN1300116C (zh) 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
WO2003041643A2 (en) 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
AU2005266494B2 (en) 2004-07-27 2009-09-10 Novartis Ag Inhibitors of Hsp90
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20080052278A1 (en) * 2006-08-25 2008-02-28 Semdirector, Inc. System and method for modeling value of an on-line advertisement campaign
FR2907453B1 (fr) * 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
DE102007032739A1 (de) * 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
DE102008061214A1 (de) * 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate

Also Published As

Publication number Publication date
AR081117A1 (es) 2012-06-27
BR112012012000A2 (pt) 2016-05-10
US20120238582A1 (en) 2012-09-20
DE102009054302A1 (de) 2011-05-26
EP2504314B1 (de) 2015-08-05
US8906930B2 (en) 2014-12-09
IL219872A (en) 2017-06-29
WO2011060873A1 (de) 2011-05-26
AU2010321264A1 (en) 2012-07-12
CA2781380C (en) 2017-07-25
KR20120101085A (ko) 2012-09-12
EP2504314A1 (de) 2012-10-03
CA2781380A1 (en) 2011-05-26
AU2010321264B2 (en) 2016-05-26
JP5841059B2 (ja) 2016-01-06
ES2548027T3 (es) 2015-10-13
MX2012005811A (es) 2012-06-12
CN102648178B (zh) 2015-01-07
JP2013511477A (ja) 2013-04-04
IL219872A0 (en) 2012-07-31
CN102648178A (zh) 2012-08-22

Similar Documents

Publication Publication Date Title
EA201000098A1 (ru) Производные хиназолинамида
EA200802329A1 (ru) Производные триазола ii
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA201000007A1 (ru) Производные индазоламида
EA201100872A1 (ru) Производные хиназолинамида
EA201000362A1 (ru) Производные 1,3-дигидроизоиндола
EA201100447A1 (ru) Органические соединения
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
EA201201648A1 (ru) Стимуляторы sgc
EA201201030A1 (ru) 5-алкинилпиримидины
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
EA201300052A1 (ru) [1,8]нафтиридиновые производные
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201101330A1 (ru) Замещенные пиримидины, предназначенные для лечения рака
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
EA201390347A1 (ru) Лечение заболеваний
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
EA201300442A1 (ru) ПИРРОЛИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ MetAP-2
EP2595482A4 (en) ALDOSTERONSYNTHASEHEMMER
EA201100874A1 (ru) Соединения для лечения рака
EA201100255A1 (ru) 5-алкинилпиримидины
EA201101533A1 (ru) Гетероциклические соединения в качестве ингибиторов mek